Structural Elements of the BCR Determine Permissiveness to Oncogenic RAS-Driven B-Cell Transformation. Read more about Structural Elements of the BCR Determine Permissiveness to Oncogenic RAS-Driven B-Cell Transformation.
BCL6-Mediated Escape from Negative Selection Enables RAS-Driven B-Cell Transformation. Read more about BCL6-Mediated Escape from Negative Selection Enables RAS-Driven B-Cell Transformation.
A Phosphatase Membrane-Shuttle Enables Feedback Control of B-Cell Signaling. Read more about A Phosphatase Membrane-Shuttle Enables Feedback Control of B-Cell Signaling.
Structural Surfaceomics Reveals an AML-Specific Conformation of Integrin-ß2 As an Immunotherapeutic Target. Read more about Structural Surfaceomics Reveals an AML-Specific Conformation of Integrin-ß2 As an Immunotherapeutic Target.
Integrating Transcriptomics and Proteomics for the Discovery of Novel Antigen Targets on Surface of Malignant Plasma Cells Amenable for Chimeric Antigen Receptor-T (CAR-T) Cell Approach in the Treatment of Patients with Relapsed/Refractory Multiple Myelom Read more about Integrating Transcriptomics and Proteomics for the Discovery of Novel Antigen Targets on Surface of Malignant Plasma Cells Amenable for Chimeric Antigen Receptor-T (CAR-T) Cell Approach in the Treatment of Patients with Relapsed/Refractory Multiple Myelom
Humanized Nanobody Anti-CD72 CAR-T Cells Efficiently Eliminate B-Cell Malignancies Via Improved Affinity for CD72 but Induce Persistent Antigen Downregulation In Vivo. Read more about Humanized Nanobody Anti-CD72 CAR-T Cells Efficiently Eliminate B-Cell Malignancies Via Improved Affinity for CD72 but Induce Persistent Antigen Downregulation In Vivo.
Improved Gvhd and Relapse Free Survival Outcomes in Older Acute Leukemia Patients Receiving Young Haploidentical Donor Vs Older Matched Sibling Donor Reduced Intensity Conditioning Hematopoietic Cell Transplants. Read more about Improved Gvhd and Relapse Free Survival Outcomes in Older Acute Leukemia Patients Receiving Young Haploidentical Donor Vs Older Matched Sibling Donor Reduced Intensity Conditioning Hematopoietic Cell Transplants.
Outcomes following treatment for ADA-deficient severe combined immunodeficiency: a report from the PIDTC. Read more about Outcomes following treatment for ADA-deficient severe combined immunodeficiency: a report from the PIDTC.
Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. Read more about Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC.
EBV-positive high-grade B-cell lymphoma with MYC and BCL6 rearrangements. Read more about EBV-positive high-grade B-cell lymphoma with MYC and BCL6 rearrangements.
